193 related articles for article (PubMed ID: 32552128)
1. Toxicological considerations in the treatment of axial spondylo-arthritis.
Marino F; D'Angelo S; Masala IF; Gerratana E; Nucera V; La Corte L; Giallanza M; Sarzi-Puttini P; Atzeni F
Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):663-672. PubMed ID: 32552128
[TBL] [Abstract][Full Text] [Related]
2. Safety of treatment options for spondyloarthritis: a narrative review.
D'Angelo S; Carriero A; Gilio M; Ursini F; Leccese P; Palazzi C
Expert Opin Drug Saf; 2018 May; 17(5):475-486. PubMed ID: 29505325
[TBL] [Abstract][Full Text] [Related]
3. New evidence on the management of spondyloarthritis.
Sieper J; Poddubnyy D
Nat Rev Rheumatol; 2016 May; 12(5):282-95. PubMed ID: 27052489
[TBL] [Abstract][Full Text] [Related]
4. Concerns about the safety of anti-TNF agents when treating rheumatic diseases.
Atzeni F; Nucera V; Gerratana E; Cirillo M; Marino F; Miceli G; Sangari D; Boccassini L; Masala IF
Expert Opin Drug Saf; 2020 Jun; 19(6):695-705. PubMed ID: 32401624
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for the treatment of axial spondyloarthritis.
Rademacher J; Poddubnyy D
Expert Opin Emerg Drugs; 2018 Mar; 23(1):83-96. PubMed ID: 29475394
[TBL] [Abstract][Full Text] [Related]
6. The Effect of TNF Inhibition on Bone Density and Fracture Risk and of IL17 Inhibition on Radiographic Progression and Bone Density in Patients with Axial Spondyloarthritis: a Systematic Literature Review.
Ashany D; Stein EM; Goto R; Goodman SM
Curr Rheumatol Rep; 2019 Mar; 21(5):20. PubMed ID: 30868279
[TBL] [Abstract][Full Text] [Related]
7. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
Colebatch AN; Marks JL; Edwards CJ
Cochrane Database Syst Rev; 2011 Nov; (11):CD008872. PubMed ID: 22071858
[TBL] [Abstract][Full Text] [Related]
8. New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents.
Toussirot E
Expert Opin Pharmacother; 2017 Feb; 18(3):275-282. PubMed ID: 28099816
[TBL] [Abstract][Full Text] [Related]
9. Biological therapies in the spondyloarthritides--the current state.
Braun J; Sieper J
Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for the treatment of axial and peripheral spondyloarthritis.
Braun J; Kiltz U; Heldmann F; Baraliakos X
Expert Opin Emerg Drugs; 2015 Mar; 20(1):1-14. PubMed ID: 25575936
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological therapy of spondyloarthritis.
Palazzi C; D'Angelo S; Gilio M; Leccese P; Padula A; Olivieri I
Expert Opin Pharmacother; 2015; 16(10):1495-504. PubMed ID: 26073668
[TBL] [Abstract][Full Text] [Related]
12. 2018 APLAR axial spondyloarthritis treatment recommendations.
Tam LS; Wei JC; Aggarwal A; Baek HJ; Cheung PP; Chiowchanwisawakit P; Dans L; Gu J; Hagino N; Kishimoto M; Reyes HM; Soroosh S; Stebbings S; Whittle S; Yeap SS; Lau CS
Int J Rheum Dis; 2019 Mar; 22(3):340-356. PubMed ID: 30816645
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological management of axial spondyloarthritis in adults.
Toussirot E
Expert Opin Pharmacother; 2019 Aug; 20(12):1483-1491. PubMed ID: 31095430
[No Abstract] [Full Text] [Related]
14. Nonsteroidal Antiinflammatory Drugs as Potential Disease-Modifying Medications in Axial Spondyloarthritis.
Wang R; Bathon JM; Ward MM
Arthritis Rheumatol; 2020 Apr; 72(4):518-528. PubMed ID: 31705611
[TBL] [Abstract][Full Text] [Related]
15. Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission.
Chen X; Zhang T; Wang W; Xue J
Clin Rheumatol; 2018 Jun; 37(6):1625-1632. PubMed ID: 29667099
[TBL] [Abstract][Full Text] [Related]
16. Emerging treatment options for spondyloarthritis.
Torgutalp M; Poddubnyy D
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):472-484. PubMed ID: 31171316
[TBL] [Abstract][Full Text] [Related]
17. Do non-steroidal anti-inflammatory drugs have disease-modifying effects in spondyloarthritis?
Wendling D
Joint Bone Spine; 2013 Dec; 80(6):563-4. PubMed ID: 23831397
[No Abstract] [Full Text] [Related]
18. Profile of the use of disease modifying drugs in the Brazilian Registry of Spondyloarthritides.
Kohem CL; Bortoluzzo AB; Gonçalves CR; Braga da Silva JA; Ximenes AC; Bértolo MB; Ribeiro SL; Keiserman M; Menin R; Skare TL; Carneiro S; Azevedo VF; Vieira WP; Albuquerque EN; Bianchi WA; Bonfiglioli R; Campanholo C; Carvalho HM; da Costa IP; Duarte AL; Leite NH; Lima SA; Meirelles ES; Pereira IA; Pinheiro MM; Polito E; Resende GG; Rocha FA; Santiago MB; Sauma Mde F; Valim V; Sampaio-Barros PD
Rev Bras Reumatol; 2014; 54(1):33-7. PubMed ID: 24878789
[TBL] [Abstract][Full Text] [Related]
19. Structural progression in axial spondyloarthritis.
Aouad K; Ziade N; Baraliakos X
Joint Bone Spine; 2020 Mar; 87(2):131-136. PubMed ID: 31067506
[TBL] [Abstract][Full Text] [Related]
20. Appropriate management of axial spondyloarthritis.
LaSalle SP; Deodhar AA
Curr Rheumatol Rep; 2007 Oct; 9(5):375-82. PubMed ID: 17915093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
